SCHEMBL5048456

SCHEMBL5048456

O=C(/C=C/c1ccc(NS(=O)(=O)c2ccccn2)cc1)NO

nearest known ligand 0.66

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 20/20 0.66
HDAC8 Q9BY41 9/20 0.66
HDAC4 P56524 8/20 0.66
HDAC3 O15379 5/20 0.66
HDAC7 Q8WUI4 5/20 0.66
HDAC2 Q92769 5/20 0.66
HDAC10 Q969S8 5/20 0.66
HDAC11 Q96DB2 5/20 0.66
HDAC6 Q9UBN7 5/20 0.66
HDAC9 Q9UKV0 5/20 0.66
HDAC5 Q9UQL6 5/20 0.66
BRD4 O60885 1/20 0.54
ESR1 P03372 1/20 0.54
PTGS1 P23219 1/20 0.54
PDE4A P27815 1/20 0.54
PIK3CA P42336 1/20 0.54
HTR6 P50406 1/20 0.54
PDE4D Q08499 1/20 0.54
ASPH Q12797 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5020746 0.87 HDAC1 (0.49) HDAC1HDAC8HDAC4HDAC3HDAC7
SCHEMBL1403258 0.80 HDAC1 (1.00) HDAC1HDAC8HDAC4HDAC3HDAC7
SCHEMBL1403256 0.80 HDAC1 (1.00) HDAC1HDAC8HDAC4HDAC3HDAC7
SCHEMBL3918083 0.79 HDAC1 (0.57) HDAC1HDAC8HDAC4HDAC3HDAC7
SCHEMBL3918081 0.79 HDAC1 (0.57) HDAC1HDAC8HDAC4HDAC3HDAC7
SCHEMBL5020619 0.77 HDAC1 (1.00) HDAC1HDAC8HDAC4HDAC3HDAC7
SCHEMBL1287618 0.77 HDAC1 (1.00) HDAC1HDAC8HDAC4HDAC3HDAC7
SCHEMBL1287621 0.77 HDAC1 (1.00) HDAC1HDAC8HDAC4HDAC3HDAC7
SCHEMBL5020623 0.76 HDAC1 (0.72) HDAC1HDAC8HDAC4HDAC3HDAC7
SCHEMBL8164647 0.75 GLO1 (0.55)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8796330-B2 Inhibitors of histone deacetylase and prodrugs thereof METHYLGENE INC. (CA) 2014-08-05 US disclosed
US-8796330-B2 Inhibitors of histone deacetylase and prodrugs thereof METHYLGENE INC. (CA) 2014-08-05 US disclosed
US-20140024608-A1 INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF METHYLGENE INC. (CA) 2014-01-23 US disclosed
US-20140024608-A1 INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF METHYLGENE INC. (CA) 2014-01-23 US disclosed
US-RE43343-E1 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2012-05-01 US disclosed
WO-2008074132-A1 INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF METHYLGENE INC. (CA) 2008-06-26 WO disclosed
US-20080146623-A1 INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF METHYLGENE INC. (CA) 2008-06-19 US disclosed
US-20080146623-A1 INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF METHYLGENE INC. (CA) 2008-06-19 US disclosed
US-RE39850-E1 Aryl amide, -sulfonamide, or -urea derivatives; antiproliferative, antitumor, anticarcinogenic, and/or antimetastasis agents METHYLGENE, INC. (CA) 2007-09-18 US disclosed
US-RE39850-E1 Aryl amide, -sulfonamide, or -urea derivatives; antiproliferative, antitumor, anticarcinogenic, and/or antimetastasis agents METHYLGENE, INC. (CA) 2007-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146623-A1 INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF HDAC1, HDAC3, HDAC11 HDAC1 1/4885HDAC8 9/4885HDAC4 6/4885
US-20140024608-A1 INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF HDAC1, HDAC3, HDAC11 HDAC1 1/4885HDAC8 9/4885HDAC4 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.